The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) Single-arm, Prospective, Open Clinical Study
Latest Information Update: 17 Nov 2023
At a glance
- Drugs Bevacizumab (Primary) ; Depoxythilone (Primary) ; Tislelizumab (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms UTILIZABLE
Most Recent Events
- 17 Nov 2023 Planned initiation date changed to 30 Oct 2023.
- 14 Nov 2023 New trial record